[The sensitivity of human melanoma heterotransplants to chemotherapeutic action]
Related Experiment Videos
Abstract:
There were revealed considerable individual differences in the sensitivity of human melanomas cultivated in diffusion chambers in the abdominal cavity of mice and the explants into the cheek pouches of Cricetus auratus W. to the combined action of three drugs: vincristin (or vinblastin), nitrosomethylurea, and dactinomycin. In comparing the results obtained in these two variants of investigations they proved to coincide in 3 of 5 cases. In 2 cases a negative result obtained in experimentas with Cricetus auratus W. corresponded to the positive result in experiments with diffuse chambers.
Insights
Human melanoma sensitivity to chemotherapy varies significantly between individual tumors. Two experimental models showed similar drug response results in most cases, indicating potential for cross-validation in cancer research.
Area of Science:
- Oncology
- Pharmacology
- Experimental Medicine
Context:
- Investigating individual differences in human melanoma sensitivity to chemotherapy.
- Utilizing two distinct experimental models: diffusion chambers in mice and cheek pouch explants in Cricetus auratus (golden hamster).
- Assessing the combined effects of vincristine (or vinblastine), nitrosomethylurea, and dactinomycin.
Purpose:
- To evaluate the consistency of drug sensitivity results between two different in vivo experimental systems for human melanoma.
- To identify potential discrepancies in drug response prediction based on the model used.
Summary:
- Significant individual variations in human melanoma sensitivity to a combination of vincristine, nitrosomethylurea, and dactinomycin were observed.
- The two experimental models (diffusion chambers in mice and hamster cheek pouches) yielded concordant results in 3 out of 5 cases.
- Discrepancies were noted in 2 cases, where one model showed drug sensitivity and the other did not, highlighting model-specific responses.
Impact:
- Provides insights into the reliability of different xenograft models for predicting melanoma drug response.
- Suggests the importance of considering experimental model choice in preclinical cancer drug testing.
- Contributes to understanding inter-tumor heterogeneity in drug sensitivity and its implications for personalized medicine.